In yesterday’s Wall Street session, Amicus Therapeutics Inc (NASDAQ:FOLD) shares traded at $11.54, down -2.29% from the previous session.
FOLD stock price is now -11.48% away from the 50-day moving average and -6.84% away from the 200-day moving average. The market capitalization of the company currently stands at $3.41B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $15 to $20, Morgan Stanley Upgraded its rating from Equal-Weight to Overweight for Amicus Therapeutics Inc (NASDAQ: FOLD). On September 09, 2022, Morgan Stanley recently initiated its ‘Equal-Weight’ rating on the stock quoting a target price of $14, while ‘Goldman’ rates the stock as ‘Neutral’
In other news, MCGLYNN MARGARET G, Director sold 7,500 shares of the company’s stock on Mar 05 ’24. The stock was sold for $100,500 at an average price of $13.40. Upon completion of the transaction, the Director now directly owns 59,289 shares in the company, valued at $0.68 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 04 ’24, Director MCGLYNN MARGARET G sold 7,500 shares of the business’s stock. A total of $99,675 was realized by selling the stock at an average price of $13.29. This leaves the insider owning 59,289 shares of the company worth $0.68 million. A total of 3.00% of the company’s stock is owned by insiders.
During the past 12 months, Amicus Therapeutics Inc has had a low of $9.70 and a high of $14.57. As of last week, the company has a debt-to-equity ratio of 2.78, a current ratio of 2.88, and a quick ratio of 2.52. The fifty day moving average price for FOLD is $12.98 and a two-hundred day moving average price translates $12.39 for the stock.
The latest earnings results from Amicus Therapeutics Inc (NASDAQ: FOLD) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.11, missing analysts’ expectations of -$0.06 by -0.05. This compares to -$0.19 EPS in the same period last year. The net profit margin was -37.96% and return on equity was -107.04% for FOLD. The company reported revenue of $115.08 million for the quarter, compared to $88.1 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 30.63 percent. For the current quarter, analysts expect FOLD to generate $111.74M in revenue.
Amicus Therapeutics Inc(FOLD) Company Profile
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
